Pulmonary Hypertension Associated with Interstitial Lung Disease Market Set for Robust Growth Throug
Author : John snow | Published On : 20 Mar 2026
Pulmonary Hypertension associated with Interstitial Lung Disease Market Expected to See Significant Growth Surge in Forecast Period (2025–2034) | DelveInsight
Growth in the PH-ILD market is fueled by rising awareness of the condition, enhanced diagnostic methods, and an expanding population of ILD patients. Additional momentum comes from approvals of inhaled treatments such as TYVASO and advancing targeted therapies that tackle key gaps in functional gains and slowing disease advancement.
New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight
The PH-ILD market is driven by increased disease recognition, improved diagnostic techniques, and a growing ILD patient base. Demand is further supported by the approval of inhaled therapies like TYVASO and the ongoing development of targeted treatments addressing the unmet need in functional improvement and disease progression.
DelveInsight’s Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights report offers a thorough overview of existing treatment approaches, promising PH-ILD therapies, market shares of key treatments, and PH-ILD market projections from 2020 to 2034 across the 7MM [the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan].
Key Takeaways from the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report
DelveInsight estimates the PH-ILD market in the 7MM reached USD 3 billion in 2024. The US holds the dominant share of the PH-ILD market compared to EU4, the UK, and Japan. Analysis from DelveInsight shows over 1 million diagnosed prevalent ILD cases in the 7MM in 2024, projected to rise by 2034. Leading players like Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, Halo Biosciences, Respira Therapeutics, Gossamer Bio, and more are advancing novel PH-ILD therapies. Pipeline highlights include Treprostinil liposomal, treprostinil palmitil inhalation powder, mosliciguat, H1614, Vardenafil (RT234), Seralutinib, and others—set to launch during the forecast period and reshape the market.
Discover which PH-ILD medications are expected to grab the market share @ Pulmonary Hypertension associated with Interstitial Lung Disease Market Report
Pulmonary Hypertension associated with Interstitial Lung Disease Market Dynamics
PH-ILD market trends are set to evolve significantly ahead. Progress in imaging tools like echocardiography, HRCT, and cardiac MRI boosts early identification of vascular issues in PH-ILD, supporting prompt diagnosis and better management. Innovations in inhaled drug delivery improve lung-specific absorption while minimizing side effects. With few approved options, these developments signal robust potential for new therapies, with upcoming approvals likely to broaden choices and propel growth in this under-served area.
Several promising treatments for PH-ILD are under investigation, poised to reshape the market landscape over the forecast period. Enhanced diagnosis rates and more effective emerging therapies will further boost PH-ILD market expansion across the 7MM.
Challenges persist, however, including symptom overlap (e.g., dyspnea, fatigue, exercise intolerance) that complicates distinguishing PH from ILD, plus a lack of reliable biomarkers delaying diagnosis. Limited pipeline options, reimbursement hurdles, and rising competition could stifle progress, limit access to new therapies, and slow innovation.
PH-ILD also imposes a heavy economic load, affecting patients' quality of life. Growth may be curbed by therapy failures, high costs, reimbursement barriers, specialist shortages, undiagnosed cases, and low disease awareness.
Pulmonary Hypertension associated with Interstitial Lung Disease Treatment Market
The PH-ILD treatment arena is undergoing major shifts, driven by heightened awareness, better diagnostics and imaging, and new inhaled therapies targeting lung vessels. Though still a severe, progressive threat, the focus is moving to options that enhance function and curb progression. Past treatments were scarce, often borrowed from PAH protocols.
Off-label use of PAH drugs like PDE5 inhibitors (e.g., sildenafil) is common for their vasodilatory benefits and safety. ERAs such as ambrisentan and bosentan are used carefully due to oxygenation risks in ILD. Prostacyclin options like treprostinil and iloprost come in inhaled or injected forms, but systemic issues highlight inhaled TYVASO's advantages for localized action with less exposure.
In May 2025, the FDA approved YUTREPIA (treprostinil) inhalation powder to boost exercise ability in adults with PAH and PH-ILD. Using Liquidia’s PRINT technology, it ensures consistent deep-lung delivery via a user-friendly, breath-activated device—the first dry powder prostacyclin designed to improve convenience and adherence.
Learn more about the PH-ILD treatment options @ Pulmonary Hypertension associated with Interstitial Lung Disease Treatment Guidelines
Pulmonary Hypertension associated with Interstitial Lung Disease Emerging Drugs and Companies
Notable pipeline candidates include treprostinil liposomal (Pharmosa BioPharm/Liquidia Corporation), treprostinil palmitil inhalation powder (Insmed), mosliciguat (Roivant Sciences/Pulmovant), H1614 (Halo Biosciences), and others, targeting varied pathways for better outcomes.
Liposomal treprostinil, dosed twice daily via a smart nebulizer, offers prolonged lung delivery with fewer peaks and reduced irritation, positioning it as a strong Phase III contender. Insmed's TPIP, an inhaled prostacyclin agonist, is advancing through Phase II/III, with encouraging interim data and plans for Phase III initiation in PH-ILD.
Gossamer Bio's seralutinib, an inhaled tyrosine kinase inhibitor targeting PDGFR, CSF1R, and c-KIT, is progressing toward Phase III development in PH-ILD, supported by strategic partnerships. Halo Biosciences' H1614, targeting hyaluronan synthesis, represents a novel anti-inflammatory and anti-fibrotic approach, with early clinical data supporting further development.
These emerging therapies promise to redefine the PH-ILD market, establishing new standards of care and accelerating innovation upon approval.
To know more about new treatment for PH-ILD, visit @ Pulmonary Hypertension associated with Interstitial Lung Disease Management
Recent Developments in the Pulmonary Hypertension associated with Interstitial Lung Disease Market
Recent milestones highlight strong momentum: Insmed reported positive Phase IIb results for TPIP, demonstrating improvements in pulmonary vascular resistance, exercise capacity, and biomarkers. Liquidia’s YUTREPIA received FDA approval for PAH and PH-ILD, marking a major advancement in inhaled prostacyclin therapy. Gossamer Bio continues to advance late-stage development programs, reinforcing confidence in next-generation treatments. Pulmonary
Hypertension associated with Interstitial Lung Disease Overview
PH-ILD arises as a chronic and progressive complication of interstitial lung diseases such as idiopathic pulmonary fibrosis, connective tissue disease-associated ILD, or hypersensitivity pneumonitis. Fibrotic lung damage elevates pulmonary arterial pressure, placing strain on the heart and lungs. Symptoms like worsening dyspnea, fatigue, and exercise intolerance significantly impact quality of life and increase mortality risk without timely intervention.
Diagnosis remains challenging due to symptom overlap with ILD, requiring tools such as echocardiography, pulmonary function tests, HRCT, and right heart catheterization for confirmation. Early detection in high-risk populations is critical to improving outcomes.
Pulmonary Hypertension associated with Interstitial Lung Disease Epidemiology Segmentation
This section outlines historical, current, and projected patient trends across the 7MM, highlighting key drivers of epidemiological growth. The report covers total and subtype-specific diagnosed prevalent cases of ILD and PH-ILD, along with gender-based segmentation from 2020 to 2034.
Download the report to understand which factors are driving PH-ILD epidemiology trends @ Pulmonary Hypertension associated with Interstitial Lung Disease Treatment Algorithm
Pulmonary Hypertension associated with Interstitial Lung Disease Report Metrics Details Study Period 2020–2034 Pulmonary Hypertension associated with Interstitial Lung Disease Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Pulmonary Hypertension associated with Interstitial Lung Disease Market Size in 2024 USD 3 Billion Key Pulmonary Hypertension associated with Interstitial Lung Disease Companies Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, Halo Biosciences, Respira Therapeutics, Gossamer Bio, and others Key Pulmonary Hypertension associated with Interstitial Lung Disease Therapies Treprostinil liposomal, treprostinil palmitil inhalation powder, mosliciguat, H1614, Vardenafil (RT234), Seralutinib, and others Scope of the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report
Pulmonary Hypertension associated with Interstitial Lung Disease Therapeutic Assessment: Pulmonary Hypertension associated with Interstitial Lung Disease current marketed and emerging therapies Pulmonary Hypertension associated with Interstitial Lung Disease Market Dynamics: Conjoint Analysis of Emerging Pulmonary Hypertension associated with Interstitial Lung Disease Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Hypertension associated with Interstitial Lung Disease Market Access and Reimbursement.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: [email protected]
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
